중동 및 아프리카 자연살해세포(NK) 치료제 시장 – 2030년까지의 산업 동향 및 예측

중동 및 아프리카 자연살해세포(NK) 치료제 시장 분석 및 통찰력

중동 및 아프리카 자연살해세포(NK) 치료제 시장은 제조업체가 시장에 신제품을 출시하는 데 영향을 미치는 더 나은 치료제 옵션에 대한 필요성이 증가하고, 수요를 증가시키고, 시장 성장을 이끄는 R&D 투자를 증가시키는 것과 같은 특징을 포함합니다. 현재 다양한 연구가 진행 중이며, 제조업체가 새롭고 혁신적인 NK 세포 치료제를 개발할 수 있는 경쟁 우위를 만들어 줄 것으로 예상되며, 이는 시장 성장을 위한 다양한 다른 기회를 제공할 것으로 예상됩니다. 그러나 세포의 특이성 부족과 생체 내 생존율 저하, 그리고 치료제와 관련된 높은 비용은 예측 기간 동안 시장 성장을 제한할 것으로 예상됩니다.

중동 및 아프리카 자연살해세포(NK) 치료제 시장은 긍정적이며 질병의 진행을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 중동 및 아프리카 자연살해세포(NK) 치료제 시장이 2023년에서 2030년까지의 예측 기간 동안 40.8%의 CAGR로 성장할 것이라고 분석합니다.

중동 및 아프리카 자연살해세포(NK) 치료제 시장 보고서는 시장 점유율, 새로운 개발, 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 창출 기회, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신에 대한 분석에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 당사에 문의하여 분석가 브리핑을 받으세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.

Market Definition

Natural killer (NK) cells are large granular lymphocytes that have the ability to quickly respond to a pathological challenge. They are important components of the innate immune system and play an important role in generating an immune response against malignancies and infectious diseases caused by viral pathogens. They have been recognized to induce the direct killing of targeted cells involving cancer cells. They have the ability to recognize the multitude of infected cells without being dependent on a single antigen-expressing cell.

NK cells secrete cytokines and chemokines that recruit other immune cells such as T cells and B cells, which enhances the immune response against the tumor cells. As NK cells do not express T cell receptors, they induce a low risk of graft-versus-host disease. Moreover, iPSC cell lines derived NK cell therapy that is CAR-NK therapy overcomes the need for a long and complex manufacturing process that allows patients with aggressive tumors to afford tumor treatment as soon as possible. Along with this iPSC derived NK cells can be infused repeatedly, which enhances the immune response with dose regulation.

Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

• Increase in Patient Population with Chronic Diseases

Chronic diseases are diseases that generally occur in older adults that can be controlled but not cured such as heart disease, arthritis, diabetes, stroke, or cancer. They are a worldwide healthcare problem concern. The change in lifestyle along with physical inactivity, unhealthy diet, and tobacco use is increasing the burden of chronic diseases all over the world.

An increasing number of patients population with chronic diseases led the scientist and researchers to work on a new innovative therapeutic approach so as to provide patients with the best curative treatment option, which can be achieved by using NK cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.

• Rise in Awareness about Immunotherapies

As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted a lot of attention in recent years for the treatment of various types of malignancies. Among the immunotherapies, CAR–T cell therapies have been studied and were used as well but have several limitations, which led to the development of NK cell therapies. As a drug based on an NK cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.

This is why several organizations and market players are launching a campaign to enhance awareness regarding NK cell therapies.

OPPORTUNITY

•  Strategic Initiatives by Market Players

Various strategic initiatives are adopted by market players which involve expansion, acquisition, and collaboration among others. These initiatives help them to increase the company’s product portfolio leading to market expansion and hence enhancing the product demand among customers, which ultimately leads the players to earn maximum revenue.

As the demand for effective and affordable NK cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.

RESTRAINT/CHALLENGE

• Lack of Specificity and Poor In Vivo Survival of the cells

Lack of specificity and poor in-vivo survival of NK cells poses a challenge in front of manufacturers dealing in the market. The lack of specificity of NK cells leads to targeting the wrong cells, which can lead to ineffective treatment. Along with this, the lack of specificity and poor in-vivo survival of NK cells also reduces the therapeutic effect of administered NK cell therapy.

Such problems decrease the credibility of therapy used in clinical trials and pose a challenge in front of manufacturers while getting approval.

Recent Developments

• In January 2022, Takeda acquired Adaptate biotherapeutics to develop novel gamma delta (γδ) T cell engager therapies targeting solid tumors. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition helped the company to focus on R&D.
• In December 2021, Nektar Therapeutics announced phase 1b data for novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of immune regulating Treg cells. This has helped the company to focus on R&D for further phases.

Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Scope

The Middle East and Africa natural killer (NK) cell therapeutics market is segmented into five notable segments based on therapeutics, approaches, application, end-user, and distribution channel. The growth among these segments will help you analyze niche pockets of growth and strategies to approach the market and determine the core application areas and the difference in the target markets.

Therapeutics

• NK Cell Therapies
• NK Cell Directed Antibodies

Based on therapeutics, the market is segmented into NK cell therapies and NK cell directed antibodies.

Approaches

• Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
• Bispecific Antibodies

Based on approaches, the market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.

Application

• Cancer
• Immunoproliferative Disorders
• Acute Infectious Diseases
•  Gastrointestinal Diseases
• Others

Based on application, the market is segmented into cancer, immunoproliferative disorders, acute infectious diseases, gastrointestinal diseases, and others.

End User

• Research & Academic Institutes
• Hospitals
•  Specialty Clinics

Based on end user, the market is segmented into hospitals, specialty clinics, and research & academic institutes.

Distribution Channel

• Hospital Pharmacies
•  Direct Tender
•  Others

Based on distribution channel, the market is segmented into hospital pharmacies, direct tender, and others.

Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Regional Analysis/Insights

The Middle East and Africa natural killer (NK) cell therapeutics market is categorized into five notable segments: therapeutics, approaches, application, end-user, and distribution channel.

The countries covered in this market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.

Saudi Arabia is dominating the Middle East and Africa natural killer (NK) cell therapeutics market.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and the challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Natural Killer (NK) Cell Therapeutics Market Share Analysis

중동 및 아프리카 자연살해세포(NK) 치료제 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 중동 및 아프리카 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

중동 및 아프리카 자연 살해(NK) 세포 치료제 시장의 주요 기업으로는 브리스톨 마이어스 스퀴브, 사노피, 다케다 제약 등이 있습니다.

SKU-66607